Eikon Therapeutics, Inc. EIKN Proceeds from issuance of redeemable convertible preferred stock
Proceeds from issuance of redeemable convertible preferred stock at other companies
Other financials
Where this comes from
Reported directly by Eikon Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock.
The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eikon Therapeutics, Inc. 's proceeds from issuance of redeemable convertible preferred stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eikon Therapeutics, Inc. 's proceeds from issuance of redeemable convertible preferred stock?
- Eikon Therapeutics, Inc. (EIKN) reported proceeds from issuance of redeemable convertible preferred stock of $350.21M in Q1 2025.